LC
TEVA icon

Landaas & Company’s Teva Pharmaceuticals TEVA Stock Holding History

Landaas & Company’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,007
Closed -$24K – 279
2018
Q2 		$24K Buy
+1,007
New +$20.5K 0.02% 209
2018
Q1 		– Sell
-1,007
Closed -$19K – 272
2017
Q4 		$19K Sell
1,007
-84
-8% -$1.26K 0.02% 221
2017
Q3 		$19K Buy
+1,091
New +$24.5K 0.02% 217

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Landaas & Company's TEVA Position: Q3 2018 in Review

Landaas & Company sold out of Teva Pharmaceuticals (TEVA) in Q3 2018, closing a stake of 1,007 shares — an estimated $24K sold.

Landaas & Company first reported a position in TEVA in Q3 2017 and held it in 3 quarters. The position peaked at $24K in Q2 2018. 556 funds tracked by Wall St. Rank hold TEVA as of Q3 2018.

  • Landaas & Company reported no remaining Teva Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Landaas & Company sold 1,007 Teva Pharmaceuticals shares in Q3 2018, an estimated $24K.
  • Landaas & Company first reported a position in Teva Pharmaceuticals in Q3 2017 and held it in 3 quarters.
  • Landaas & Company's Teva Pharmaceuticals position peaked at $24K in Q2 2018.
  • 556 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2018.

Based on Landaas & Company's 13F filing for Q3 2018, filed 14 Nov 2018.